Correlation of CA125 with adnexsa tumors: A literature review
DOI: https://doi.org/10.33024/hjk.v20i1.2238
Biomarker Kadar CA125 Kanker Ovarium Tumor Adneksa
Abstract
Background: Adnexal tumors represent a broad spectrum of gynecological conditions ranging from benign lesions to malignant ovarian tumors with high mortality rates. Delayed diagnosis remains a major clinical challenge, particularly in ovarian cancer. Cancer Antigen 125 (CA125) is the most widely used biomarker for assessing the risk of malignancy in adnexal masses; however, its sensitivity and specificity are limited, especially in early-stage disease and non-malignant conditions. Previous studies have reported inconsistent results regarding the correlation between CA125 levels and adnexal tumors.
Purpose: To analyze the correlation between CA125 levels and adnexal tumors.
Method: A literature review with a meta-analysis approach was conducted following the PRISMA guidelines. Relevant studies published between 2015 and 2025 were identified through PubMed, Scopus, Web of Science, and ScienceDirect databases. Eligible studies were quantitatively analyzed to assess the strength of the correlation between CA125 levels and the nature of adnexal tumors. Statistical analyses were performed using fixed-effect or random-effect models based on inter-study heterogeneity.
Results: The meta-analysis demonstrated an association between elevated CA125 levels and malignant adnexal tumors, although substantial variability among studies was observed. The heterogeneity reflected differences in study populations, menopausal status, diagnostic methods, and tumor histopathology.
Conclusion: CA125 plays a supportive role as a biomarker in the evaluation of adnexal tumors, particularly for malignancy risk stratification and clinical monitoring. Nevertheless, due to its limited sensitivity and specificity, CA125 should not be used as a standalone diagnostic tool and must be integrated with clinical assessment and imaging modalities. This meta-analysis emphasizes the importance of a multimodal diagnostic approach in adnexal tumor management.
Suggestion: Further research should involve a combination of other biomarkers and imaging examinations to improve the predictability of malignancy.
Keywords: Adnexal Tumor: Biomarker; CA125 Level; Ovarian Cancer.
Pendahuluan: Tumor adneksa merupakan masalah kesehatan ginekologi yang sering dijumpai dan mencakup spektrum luas dari lesi jinak hingga keganasan ovarium dengan mortalitas tinggi. Keterlambatan diagnosis, terutama pada kanker ovarium, menjadi tantangan utama dalam praktik klinis. Cancer Antigen 125 (CA125) merupakan biomarker yang paling banyak digunakan untuk membantu penilaian risiko keganasan tumor adneksa, namun memiliki keterbatasan sensitivitas dan spesifisitas, terutama pada stadium awal dan kondisi non-maligna. Bukti ilmiah mengenai korelasi CA125 dengan tumor adneksa masih menunjukkan hasil yang bervariasi.
Tujuan: Untuk menganalisis korelasi antara kadar CA125 dengan tumor adneksa.
Metode: Penelitian menggunakan pendekatan literature review dengan metode meta-analisis sesuai pedoman PRISMA. Penelusuran literatur dilakukan pada basis data PubMed, Scopus, Web of Science, dan ScienceDirect untuk artikel yang dipublikasikan pada periode 2015–2025. Artikel yang memenuhi kriteria inklusi dianalisis secara kuantitatif untuk menilai kekuatan korelasi antara kadar CA125 dan sifat tumor adneksa. Analisis statistik dilakukan menggunakan model fixed effect atau random effect berdasarkan tingkat heterogenitas antar studi..
Hasil: Adanya hubungan antara peningkatan kadar CA125 dengan sifat keganasan tumor adneksa, meskipun ditemukan variasi hasil antar penelitian. Heterogenitas antar studi mencerminkan perbedaan karakteristik populasi, status menopause, metode pemeriksaan, serta jenis histopatologi tumor.
Simpulan: CA125 memiliki peran sebagai biomarker pendukung dalam evaluasi tumor adneksa, terutama dalam stratifikasi risiko keganasan dan pemantauan klinis. Namun, keterbatasan sensitivitas dan spesifisitas menegaskan bahwa CA125 tidak dapat digunakan sebagai alat diagnostik tunggal dan harus dikombinasikan dengan penilaian klinis serta modalitas diagnostik lainnya. Meta-analisis ini memperkuat pentingnya pendekatan multimodal dalam diagnosis tumor adneksa.
Saran: Penelitian lanjutan sebaiknya melibatkan kombinasi penanda biomolekuler lain dan pemeriksaan pencitraan untuk meningkatkan prediktabilitas keganasan.
Kata Kunci: Biomarker; Kadar CA125; Kanker Ovarium; Tumor Adneksa.
Downloads
References
Aditiyono, A., Harsono, A. B., & Susanto, H. (2018). CA 125 dan risk of malignancy index (RMI) 2 sebagai prediktor keganasan tumor ovarium tipe epitel. Mandala Of Health, 11(1), 18-30.
Ayuadiningsih, R. A. W., & Trusda, S. A. D. (2021). Karateristik Pasien Karsinoma Ovarium Berdasarkan Gejala Klinis, Penyakit Penyerta, Komplikasi, dan Usia di Ruang Rawat Inap Rsud Al-Ihsan Bandung. Jurnal Riset Kedokteran, 1-8.
Barreñada, L., Ledger, A., Dhiman, P., Collins, G., Wynants, L., Verbakel, J. Y., & Van Calster, B. (2024). ADNEX risk prediction model for diagnosis of ovarian cancer: systematic review and meta-analysis of external validation studies. BMJ medicine, 3(1), e000817.
Behnamfar, F., Esmaeilian, F., Adibi, A., & Rouholamin, S. (2022). Comparison of ultrasound and tumor marker CA125 in diagnosis of adnexal mass malignancies. Advanced Biomedical Research, 11(1), 18.
Deng, S., Zhou, Y., Lin, J., Xiang, Z., Liu, L., Xie, N., & Sun, Y. (2024). Survival analysis of gynecological cancers in Southeast China, 2011–2020: A population-based study. Cancer Epidemiology, 92, 102641.
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., & Patankar, M. S. (2014). MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular cancer, 13(1), 129.
Gawełczyk, W., Soczyńska, J., Muzyka, A., Rydzek, J., Majcherczyk, K., Żołyniak, M., & Woźniak, S. (2025). Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies. International Journal of Molecular Sciences, 26(23), 11702.
Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno III, D. E., & NCD Global Health Research Group of Association of Pacific Rim Universities (APRU). (2022). Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers, 14(9), 2230.
Nadhiroh, A. M., Supatmi, S., Hendarsih, E., Sumariyah, S., Kusnani, A., Rahayu, S., & Murni, R. D. (2025). Karakteristik pasien kanker pada perempuan di poli onkologi rsud haji provinsi jawa timur. Jomis (Journal of Midwifery Science), 9(1), 28-40.
Pangaribuan, M. T. M., Razali, R. R., & Darmawi, D. (2025). Diagnostic Accuracy of CA-125 Levels for Ovarian Tumor Patients with Suspected Malignancy. Indonesian Journal of Cancer, 19(1), 1-8.
Putri, R. E., Yenita, Y., & Yusrawati, Y. (2025). Hubungan gambaran histopatologi dengan gambaran klinis kanker ovarium di rsup dr. M. Djamil padang 2018-2019. Sinergi: Jurnal Riset Ilmiah, 2(4), 1765-1781.
Rahayu, D. R. D., Nugroho, E., & Saputri, M. J. (2024). Hubungan Kadar CA-125 dengan Derajat Diferensiasi Kanker Ovarium Tipe Epithelial Tahun 2020–2022 di RSUD Abdul Wahab Sjahranie Samarinda. Ranah Research: Journal of Multidisciplinary Research and Development, 6(6), 2517-2525.
Rahmalia, K., Sudiarta, K. E., Setianingsih, H., & Diarsvitri, W. (2024). The characteristics of sociodemography, histopathologic features, stage, and management of ovarian cancer in Dr. Ramelan Navy Hospital Surabaya. Indonesian Journal of Cancer, 18(2), 131-137.
Scher, H. I., & Eastham, J. A. (2022). 87: Benign and malignant diseases of the prostate. Harrison’s principles of internal medicine. 21st ed. McGraw Hill.
Sharma, D., & Vinocha, A. (2020). Benign ovarian cysts with raised CA-125 levels: do we need to evaluate the fallopian tubes?. Journal of laboratory physicians, 12(04), 276-280.
Vitale, S. G., Capriglione, S., Zito, G., Lopez, S., Gulino, F. A., Di Guardo, F., & Laganà, A. S. (2019). Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of gynecology and obstetrics, 299(2), 299-315.
Wang, C. W., Weaver, S. D., Boonpattrawong, N., Schuster-Little, N., Patankar, M., & Whelan, R. J. (2024). A revised molecular model of ovarian cancer biomarker CA125 (MUC16) enabled by long-read sequencing. Cancer Research Communications, 4(1), 253-263.
Wu, Y., Miao, K., Wang, T., Xu, C., Yao, J., & Dong, X. (2023). Prediction model of adnexal masses with complex ultrasound morphology. Frontiers in Medicine, 10, 1284495.
Zhang, X. Y., Hong, L. L., & Ling, Z. Q. (2024). MUC16: clinical targets with great potential. Clinical and experimental medicine, 24(1), 101.
Zhang, Z., Zheng, X., Zhang, M., Li, J., Zhao, J., Zheng, J., & Wang, S. (2021). Pathological features of persistent adnexal masses in pregnancy. Annals of Translational Medicine, 9(12), 973.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Holistik Jurnal Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
